The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for Neuroinflammation

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Wan, Wenbin ^a   Cao, Lan ^a   Khanabdali, Ramin ^b   Kalionis, Bill ^b   Tai, Xiantao ^c   Xia, Shijin ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c YUNNAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CHEMOKINE RECEPTOR CXCR4; HIGH MOBILITY GROUP B1 PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TOLL LIKE RECEPTOR;

DISEASE COURSE; HUMAN; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PATHOLOGY; REVIEW; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEURALGIA;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; HMGB1 PROTEIN; HUMANS; MOLECULAR TARGETED THERAPY; NEURALGIA; TOLL-LIKE RECEPTORS;

EID: 84973111663     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/6430423     Document Type: Review

References (95)

1. I. Yalcin, F. Barthas, and M. Barrot, "Emotional consequences of neuropathic pain: insight from preclinical studies," Neuroscience and Biobehavioral Reviews, vol. 47, pp. 154-164, 2014.
2. T. Maeda, M. Ozaki, Y. Kobayashi, N. Kiguchi, and S. Kishioka, "HMGB1 as a potential therapeutic target for neuropathic pain," Journal of Pharmacological Sciences, vol. 123, no. 4, pp. 301-305, 2013.
3. S. Collins, M. J. Sigtermans, A. Dahan, W. W. A. Zuurmond, and R. S. G. M. Perez, "NMDA receptor antagonists for the treatment of neuropathic pain," Pain Medicine, vol. 11, no. 11, pp. 1726-1742, 2010.
4. R. Baron, "Mechanisms of disease: neuropathic pain-a clinical perspective," Nature Clinical Practice Neurology, vol. 2, no. 2, pp. 95-106, 2006.
5. I. Gilron and A. H. Dickenson, "Emerging drugs for neuropathic pain," Expert Opinion on Emerging Drugs, vol. 19, no. 3, pp. 329-341, 2014.
6. N. Attal, M. Lanteri-Minet, B. Laurent, J. Fermanian, and D. Bouhassira, "The specific disease burden of neuropathic pain: results of a French nationwide survey," Pain, vol. 152, no. 12, pp. 2836-2843, 2011.
7. C. Schaefer, A. Sadosky, R. Mann et al., "Pain severity and the economic burden of neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study," Clinico Economics and Outcomes Research, vol. 6, pp. 483-496, 2014.
8. A. Szczudlik, J. Dobrogowski, J. Wordliczek et al., "Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the study of pain and the Polish Neurological Society-part one," Neurologia i Neurochirurgia Polska, vol. 48, no. 4, pp. 262-271, 2014.
9. J.H. Vranken, "Elucidation of pathophysiology and treatment of neuropathic pain," Central Nervous System Agents in Medicinal Chemistry, vol. 12, no. 4, pp. 304-314, 2012.
10. E. K. Krumova, C. Geber, A. Westermann, and C. Maier, "Neuropathic pain: is quantitative sensory testing helpful?" Current Diabetes Reports, vol. 12, no. 4, pp. 393-402, 2012.
11. M. Brod, B. Pohlman, S. I. Blum, A. Ramasamy, and R. Carson, "Burden of illness of diabetic peripheral neuropathic pain: a qualitative study," Patient, vol. 8, no. 4, pp. 339-348, 2015.
12. S. Pereira, F. Fontes, T. Sonin et al., "Neurological complications of breast cancer: study protocol of a prospective cohort study," BMJ Open, vol. 4, no. 10, Article IDe006301, 2014.
13. N. Attal, C. Fermanian, J. Fermanian, M. Lanteri-Minet, H. Alchaar, and D. Bouhassira, "Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?" Pain, vol. 138, no. 2, pp. 343-353, 2008.
14. V. Erthal and P. Nohama, "Treatment for neuropathic pain and chronic inflammation using LASER in animal models," in Proceedings of the 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC '15), pp. 1315-1318, Milan, Italy, August 2015.
15. Y. Kobayashi, N. Kiguchi, Y. Fukazawa, F. Saika, T. Maeda, and S. Kishioka, "Macrophage-T cell interactions mediate neuropathic pain through the glucocorticoid-induced tumor necrosis factor ligand system," The Journal of Biological Chemistry, vol. 290, no. 20, pp. 12603-12613, 2015.
16. L. H. Hang, S. N. Li, H. Luo et al., "Connexin 43 mediates CXCL12 production from spinal dorsal horn to maintain bone cancer pain in Rats," Neurochemical Research, vol. 41, no. 5, pp. 1200-1208, 2016.
17. L. Vas and R. Pai, "Reversal of complex regional pain syndrome type 2 and the subsequent management of complex regional pain syndrome type 1 occurring after corrective surgery for residual ulnar claw," Pain Medicine, vol. 15, no. 6, pp. 1059-1063, 2014.
18. B. Afsharimani, K. Kindl, P. Good, and J. Hardy, "Pharmacological options for the management of refractory cancer pain-what is the evidence?" Supportive Care in Cancer, vol. 23, no. 5, pp. 1473-1481, 2015.
19. X. Kuang, Y. Huang, H.-F. Gu et al., "Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats," European Journal of Pharmacology, vol. 676, no. 1-3, pp. 51-56, 2012.
20. C. R. Jutzeler, E. Huber, M. F. Callaghan et al., "Association of pain and CNS structural changes after spinal cord injury," Scientific Reports, vol. 6, Article ID18534, 2016.
21. Y. Chen, X. Chen, J. Yu et al., "JAB1 is involved in neuropathic pain by regulating JNK and NF-κB activation after chronic constriction injury," Neurochemical Research, vol. 41, no. 5, pp. 1119-1129, 2016.
22. S. Wang, H. Xu, L. Zou et al., "LncRNA uc.48+ is involved in diabetic neuropathic pain mediated by the P2X3 receptor in the dorsal root ganglia," Purinergic Signalling, vol. 12, no. 1, pp. 139-148, 2016.
23. A. Taheri, A. Farbood, R. Heshmat et al., "The effect of transdermal nitroglycerin on pain control in diabetic patients with peripheral neuropathy," Journal of Diabetes & Metabolic Disorders, vol. 14, article 86, 2015.
24. G.W. Jay and R. L. Barkin, "Neuropathic pain: etiology, pathophysiology, mechanisms, and evaluations," Disease-a-Month, vol. 60, no. 1, pp. 6-47, 2014.
25. U. Andersson and K. J. Tracey, "HMGB1 is a therapeutic target for sterile inflammation and infection," Annual Review of Immunology, vol. 29, pp. 139-162, 2011.
26. G. H. Goodwin, C. Sanders, and E. W. Johns, "A new group of chromatin associated proteins with a high content of acidic and basic amino acids," European Journal of Biochemistry, vol. 38, no. 1, pp. 14-19, 1973.
27. R. Kang, R. Chen, Q. Zhang et al., "HMGB1 in health and disease," Molecular Aspects of Medicine, vol. 40, pp. 1-116, 2014.
28. B. Holland, "Revised nomenclature for high mobility group (HMG) chromosomal proteins," Trends in Biochemical Sciences, vol. 26, no. 3, pp. 152-153, 2001.
29. K. Peter and A. Bobik, "HMGB1 signals danger in acute coronary syndrome: emergence of a new risk marker for cardiovascular death?" Atherosclerosis, vol. 221, no. 2, pp. 317-318, 2012.
30. H.M. Weir, P. J. Kraulis, C. S. Hill, A. R. C. Raine, E. D. Laue, and J.O. Thomas, "Structure of the HMGboxmotif in the B-domain of HMG1," The EMBO Journal, vol. 12, no. 4, pp. 1311-1319, 1993.
31. T. B. Lin, M. C. Hsieh, C. Y. Lai et al., "Melatonin relieves neuropathic allodynia through spinal MT2-enhanced PP2Ac and down stream HDAC4 shuttling-dependent epigenetic modification of hmgb1 transcription," Journal of Pineal Research, vol. 60, no. 3, pp. 263-276, 2016.
32. M. Magna and D. S. Pisetsky, "The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases," Molecular Medicine, vol. 20, no. 1, pp. 138-146, 2014.
33. H. Yang, P. Lundbäck, L. Ottosson et al., "Redox modification of cysteine residues regulates the cytokine activity of highmobility group box-1 (HMGB1)," Molecular Medicine, vol. 18, no. 2, pp. 250-259, 2012.
34. L. Zhu, G. Huang, J. Sheng, Q. Fu, and A. Chen, "High-mobility group box 1 induces neuron autophagy in a rat spinal root avulsion model," Neuroscience, vol. 315, pp. 286-295, 2016.
35. Y. Liu, R. Prasad, and S. H. Wilson, "HMGB1: roles in base excision repair and related function," Biochimica et Biophysica Acta, vol. 1799, no. 1-2, pp. 119-130, 2010.
36. A. Raucci, R. Palumbo, and M. E. Bianchi, "HMGB1: a signal of necrosis," Autoimmunity, vol. 40, no. 4, pp. 285-289, 2007.
37. J. K. Juranek, G. K. Daffu, J. Wojtkiewicz, D. Lacomis, J. Kofler, and A. M. Schmidt, "Receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis," Frontiers in Cellular Neuroscience, vol. 9, article 485, 2015.
38. P. Castellani, E. Balza, and A. Rubartelli, "Inflammation, DAMPs, tumor development, and progression: a vicious circle orchestrated by redox signaling," Antioxidants and Redox Signaling, vol. 20, no. 7, pp. 1086-1097, 2014.
39. Y. Tang, X. Zhao, D. Antoine et al., "Regulation of posttranslational modifications of HMGB1 during immune responses," Antioxidants & Redox Signaling, vol. 24, no. 12, pp. 620-634, 2016.
40. N. M. Agalave and C. I. Svensson, "Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain," Molecular Medicine, vol. 20, no. 1, pp. 569-578, 2015.
41. G. Basta, "Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications," Atherosclerosis, vol. 196, no. 1, pp. 9-21, 2008.
42. Y. M. Allette, M. R. Due, S. M. Wilson et al., "Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain," Brain, Behavior, and Immunity, vol. 42, pp. 169-177, 2014.
43. W. K. den Dekker, C. Cheng, G. Pasterkamp, and H. J. Duckers, "Toll like receptor 4 in atherosclerosis and plaque destabilization," Atherosclerosis, vol. 209, no. 2, pp. 314-320, 2010.
44. Y.-Q. Ma, Y.-R. Chen, Y.-F. Leng, and Z.-W. Wu, "Tanshinone IIA downregulates HMGB1 and TLR4 expression in a spinal nerve ligation model of neuropathic pain," Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 639563, 8 pages, 2014.
45. Y. Liu, W. Yan, S. Tohme et al., "Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9," Journal of Hepatology, vol. 63, no. 1, article no. 5550, pp. 114-121, 2015.
46. A. Friggeri, Y. Yang, S. Banerjee, Y.-J. Park, G. Liu, and E. Abraham, "HMGB1 inhibits macrophage activity in efferocytosis through binding to the αvβ3-integrin," American Journal of Physiology-Cell Physiology, vol. 299, no. 6, pp. C1267-C1276, 2010.
47. J.-X. Song, J.-H. Lu, L.-F. Liu et al., "HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B," Autophagy, vol. 10, no. 1, pp. 144-154, 2014.
48. + T cell differentiation by a CD24-dependent mechanism," Immunity, vol. 40, no. 3, pp. 400-413, 2014.
49. S. Balosso, J. Liu, M. E. Bianchi, and A. Vezzani, "Disulfidecontaining high mobility group box-1 promotes N-methyl-daspartate receptor function and excitotoxicity by activating tolllike receptor 4-dependent signaling in hippocampal neurons," Antioxidants and Redox Signaling, vol. 21, no. 12, pp. 1726-1740, 2014.
50. D. Yang, Q. Chen, H. Yang, K. J. Tracey, M. Bustin, and J. J. Oppenheim, "High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin," Journal of Leukocyte Biology, vol. 81, no. 1, pp. 59-66, 2007.
51. D. Yang, P. Tewary, G. de la Rosa, F. Wei, and J. J. Oppenheim, "The alarmin functions of high-mobility group proteins," Biochimica et Biophysica Acta-Gene Regulatory Mechanisms, vol. 1799, no. 1-2, pp. 157-163, 2010.
52. M. Vezzoli, P. Castellani, L. Campana et al., "Redox remodeling: a candidate regulator of HMGB1 function in injured skeletal muscle," Annals of the New York Academy of Sciences, vol. 1209, no. 1, pp. 83-90, 2010.
53. M. Chacur, E. D. Milligan, L. S. Gazda et al., "A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral perisciatic immune activation in rats," Pain, vol. 94, no. 3, pp. 231-244, 2001.
54. J. Tanaka, Y. Seki, H. Ishikura et al., "Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats," British Journal of Pharmacology, vol. 170, no. 6, pp. 1233-1241, 2013.
55. A. Vezzani, M. Maroso, S. Balosso, M.-A. Sanchez, and T. Bartfai, "IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures," Brain, Behavior, and Immunity, vol. 25, no. 7, pp. 1281-1289, 2011.
56. J. Zhang, H. Zhang, and T. Zi, "Overexpression of microRNA-141 relieves chronic constriction injury-induced neuropathic pain via targeting high-mobility group box 1," International Journal of Molecular Medicine, vol. 36, no. 5, pp. 1433-1439, 2015.
57. M. Shibasaki, M. Sasaki, M. Miura et al., "Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury," Pain, vol. 149, no. 3, pp. 514-521, 2010.
58. F. F. Zhang, N. Morioka, S. Harano et al., "Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloprotease-9 upregulation in mice with painful peripheral neuropathy," Journal of Neurochemistry, vol. 136, no. 4, pp. 837-850, 2016.
59. H. S. Hreggvidsdóttir, A. M. Lundberg, A.-C. Aveberger, L. Klevenvall, U. Andersson, and H. E. Harris, "High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor," Molecular Medicine, vol. 18, no. 2, pp. 224-230, 2012.
60. L. Campana, L. Bosurgi, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini, "Requirement of HMGB1 for stromal cellderived factor-1/CXCL12-dependent migration of macrophages and dendritic cells," Journal of Leukocyte Biology, vol. 86, no. 3, pp. 609-615, 2009.
61. K.-I. Otoshi, S.-I. Kikuchi, K. Kato, M. Sekiguchi, and S.-I. Konno, "Anti-HMGB1 neutralization antibody improves painrelated behavior induced by application of autologous nucleus pulposus onto nerve roots in rats," Spine, vol. 36, no. 11, pp. E692-E698, 2011.
62. N. M. Agalave, M. Larsson, S. Abdelmoaty et al., "Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis," Pain, vol. 155, no. 9, pp. 1802-1813, 2014.
63. Y. Nakamura, N. Morioka, H. Abe et al., "Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1," PLoS ONE, vol. 8, no. 8, Article ID e73640, 2013.
64. J. Tanaka, K. Yamaguchi, H. Ishikura et al., "Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis," Neuropharmacology, vol. 79, pp. 112-118, 2014.
65. P.-C. Ren, Y. Zhang, X.-D. Zhang et al., "High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes," Brain Research Bulletin, vol. 88, no. 4, pp. 332-337, 2012.
66. R. J. Deane, "Is RAGE still a therapeutic target for Alzheimers disease?" Future Medicinal Chemistry, vol. 4, no. 7, pp. 915-925, 2012.
67. R. Deane, I. Singh, A. P. Sagare et al., "A multimodal RAGEspecific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease," The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1377-1392, 2012.
68. W.-B. Wan, L. Cao, L.-M. Liu et al., "EGb761 provides a protective effect against Aβ1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model," PLoS ONE, vol. 9, no. 11, Article ID 0113126, 2014.
69. G. Fritz, "RAGE: a single receptor fits multiple ligands," Trends in Biochemical Sciences, vol. 36, no. 12, pp. 625-632, 2011.
70. 1-42oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and downregulation of tight junction scaffold proteins," Journal of Neurochemistry, vol. 134, no. 2, pp. 382-393, 2015.
71. R. Ray, J. K. Juranek, and V. Rai, "RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis," Neuroscience & Biobehavioral Reviews, vol. 62, pp. 48-55, 2016.
72. D. Musumeci, G. N. Roviello, and D. Montesarchio, "An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies," Pharmacology and Therapeutics, vol. 141, no. 3, pp. 347-357, 2014.
73. R. Kokkola, Å. Andersson, G. Mullins et al., "RAGE is themajor receptor for the proinflammatory activity of HMGB1 in rodent macrophages," Scandinavian Journal of Immunology, vol. 61, no. 1, pp. 1-9, 2005.
74. W. Huang, Y. Liu, L. Li et al., "HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways," Inflammation, vol. 35, no. 1, pp. 350-362, 2012.
75. P. M. LeBlanc, T. A. Doggett, J. Choi et al., "An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosisinduced tolerance through RAGE receptor," The Journal of Biological Chemistry, vol. 289, no. 11, pp. 7777-7786, 2014.
76. X. Wu, Y. Mi, H. Yang, A. Hu, Q. Zhang, and C. Shang, "The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway," Molecular and Cellular Biochemistry, vol. 380, no. 1-2, pp. 249-257, 2013.
77. V. Iori, M. Maroso, M. Rizzi et al., "Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures," Neurobiology of Disease, vol. 58, pp. 102-114, 2013.
78. Y. Okuma, K. Liu, H. Wake et al., "Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction," Neuropharmacology, vol. 85, pp. 18-26, 2014.
79. M. B. Manigrasso, J. Juranek, R. Ramasamy, and A. M. Schmidt, "Unlocking the biology of RAGE in diabetic microvascular complications," Trends in Endocrinology and Metabolism, vol. 25, no. 1, pp. 15-22, 2014.
80. V. Meneghini, V. Bortolotto, M. T. Francese et al., "Highmobility group box-1 protein and β-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-κβ Axis: relevance for Alzheimer's disease," The Journal of Neuroscience, vol. 33, no. 14, pp. 6047-6059, 2013.
81. B. Liliensiek, M. A. Weigand, A. Bierhaus et al., "Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response," The Journal of Clinical Investigation, vol. 113, no. 11, pp. 1641-1650, 2004.
82. T. Kawasaki and T. Kawai, "Toll-like receptor signaling pathways," Frontiers in Immunology, vol. 5, article 461, 2014.
83. T. Kawai and S. Akira, "The role of pattern-recognition receptors in innate immunity: update on toll-like receptors," Nature Immunology, vol. 11, no. 5, pp. 373-384, 2010.
84. T. Celhar, R. Magalhães, and A.-M. Fairhurst, "TLR7 and TLR9 in SLE: when sensing self goes wrong," Immunologic Research, vol. 53, no. 1-3, pp. 58-77, 2012.
85. Y. Xi, F. Shao, X.-Y. Bai, G. Cai, Y. Lv, and X. Chen, "Changes in the expression of the toll-like receptor system in the aging rat kidneys," PLoS ONE, vol. 9, no. 5, Article ID e96351, 2014.
86. T. Liu, Y.-J. Gao, and R.-R. Ji, "Emerging role of Toll-like receptors in the control of pain and itch," Neuroscience Bulletin, vol. 28, no. 2, pp. 131-144, 2012.
87. Y.-S. Wang, Y.-Y. Li, L.-H. Wang et al., "Tanshinone IIA attenuates chronic pancreatitis-induced pain in rats via downregulation of HMGB1 and TRL4 expression in the spinal cord," Pain Physician, vol. 18, no. 4, pp. E615-E628, 2015.
88. L. Nicotra, L. C. Loram, L. R. Watkins, and M. R. Hutchinson, "Toll-like receptors in chronic pain," Experimental Neurology, vol. 234, no. 2, pp. 316-329, 2012.
89. D. Kim, A. K. Myung, I.-H. Cho et al., "A critical role of tolllike receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity," The Journal of Biological Chemistry, vol. 282, no. 20, pp. 14975-14983, 2007.
90. L. Cao, F. Y. Tanga, and J. A. DeLeo, "The contributing role of CD14 in toll-like receptor 4 dependent neuropathic pain," Neuroscience, vol. 158, no. 2, pp. 896-903, 2009.
91. J. Qi, K. Buzas, H. Fan et al., "Painful pathways induced by TLR stimulation of dorsal root ganglion neurons," Journal of Immunology, vol. 186, no. 11, pp. 6417-6426, 2011.
92. M. Schiraldi, A. Raucci, L.M. Muñoz et al., "HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4," The Journal of Experimental Medicine, vol. 209, no. 3, pp. 551-563, 2012.
93. K. Sakamoto, A. Mizuta, K. Fujimura et al., "High-mobility group Box-1 is involved in NMDA-induced retinal injury the in rat retina," Experimental Eye Research, vol. 137, pp. 63-70, 2015.
94. M. Pedrazzi, M. Averna, B. Sparatore et al., "Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein," PLoS ONE, vol. 7, no. 8, Article ID e44518, 2012.
95. P. Schestatsky, L. Vidor, P. B. Winckler, T. G. de Araújo, and W. Caumo, "Promising treatments for neuropathic pain," Arquivos de Neuro-Psiquiatria, vol. 72, no. 11, pp. 881-888, 2014.